Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 0965 • ACR Convergence 2022
Pregnancy Outcomes in a Diverse Lupus Cohort
Julia Simard¹, Emily Liu², Eliza Chakravarty³, Amadeia Rector¹, Miranda Cantu⁴, Daniel Kuo⁵, Gary Shaw⁶, Maurice Druzin⁶, Michael Weisman⁷ and Monique Hedderson², ¹Stanford University School of Medicine, Palo Alto, CA, ²Kaiser Permanente Northern California’s Division of Research, Oakland, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City Medical Center, Redwood City, CA, ⁶Stanford University School of Medicine, Palo Alto, ⁷Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1003 • ACR Convergence 2022
Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Coral Mouriño Rodriguez¹, Irene Altabas Gonzalez¹, Iñigo Rúa-Figueroa², Norman Jimenez³, Francisco Rubiño⁴, Iñigo Hernandez Rodriguez¹, Raul Menor Almagro⁵, Esther Uriarte Isacelaya⁶, Eva Tomero Muriel⁷, Tarek Carlos Salman-Monte⁸, Irene Carrion Barbera⁹, maria Galindo¹⁰, Esther Rodriguez Almaraz¹⁰, Luis Ines Sousa¹¹ and Jose M Pego-Reigosa¹², ¹Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³IRIDIS Group, Vigo, Spain, ⁴Hospital Universitario de Jerez de la Frontera, Jerez de la frontera, Spain, ⁵Hospital Jerez de la Frontera, Cádiz, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ⁹Hospital del Mar, Rheumatology, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ¹²Hospital Meixoeiro, Vigo, Spain
Background/Purpose: Treat to Target strategies are necessary in Systemic Lupus Erythematosus (SLE). They are difficult to establish due to the heterogeneity of the disease. The…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1373 • ACR Convergence 2022
Increased Patient Contact May Mitigate Flares Among jSLE Patients
Jessica Fennell, Deanna Jannat-Khah, DrPH, MSPH and karen onel, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimizing jSLE management is crucial to prevent flares as the damage sustained during flares contributes to lifelong morbidity and mortality. The onset of the…
Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Eldon Jupe¹, Gerald Lushington², Mohan Purushothaman¹, Fabricio Pautasso¹, Georg Armstrong¹, Arif Sorathia¹, Jessica Crawley¹, Vijay Nadipelli³, Bernie Rubin⁴, Ryan Newhardt¹, Melissa Munroe¹ and Brett Adelman¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OR, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Savino Sciascia¹, Alice Barinotti², Massimo Radin², Irene Cecchi¹, Elisa Menegatti², Vittorio Modena², Daniela Rossi², Simone Baldovino², Roberta Fenoglio² and Dario Roccatello², ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…
Abstract Number: 1485 • ACR Convergence 2022
Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus
Mark Jensen¹, Ilona Nln¹, Taro Iwamoto², Jessica Dorschner³, Danielle Vsetecka³, Jacqueline Paredes¹, Ruth Fernandez Ruiz⁴, Theresa Wampler Muskardin⁵ and Timothy Niewold¹, ¹Hospital for Special Surgery, New York, NY, ²Chiba University, New York, NY, ³Mayo Clinic, Rochester, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Colton Center for Autoimmunity, NYU School of Medicine, New York, NY
Background/Purpose: To characterize regulatory surface receptors on blood plasmacytoid dendritic cells (PDCs) of lupus patients and controls to determine if receptor expression and function associates…
Abstract Number: 1677 • ACR Convergence 2022
Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells
Brian J. Mog¹, Elana R. Shaw¹, Michael S. Hwang¹, Alexander H. Pearlman¹, Sarah R. DiNapoli¹, Suman Paul¹, Chetan Bettegowda¹, Nickolas Papadopoulos¹, Sandra B. Gabelli¹, Michelle Petri², Antony Rosen¹, Shibin Zhou¹, Kenneth W. Kinzler¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
Abstract Number: 1725 • ACR Convergence 2022
Sex Differences in Autoimmune Pathogenesis and Systemic Response to High Fat Diet in Lupus-prone Mice
Gitanjali Lobo¹, Juan Meng², Xuhua Shi², Ronak Patel³, Laura Rivers⁴, Chad Hille⁵, Robert Quinet⁶, William Davis⁷, Jerald Zakem⁸, Chandana Keshavamurthy⁹, Tamika Webb-Detiege¹⁰, Zongbing You² and Xin Zhang¹¹, ¹Ochsner Clinic Foundation, Metairie, LA, ²Tulane University, New Orleans, LA, ³Ochsner, New Orleans, LA, ⁴Ochsner Medical Center, River Ridge, LA, ⁵Ochsner Clinic Foundation, New Orleans, LA, ⁶Ochsner Health, River Ridge, LA, ⁷Ochsner Medical Center, New Orleans, LA, ⁸Ochsner Health Systems, Metairie, LA, ⁹ochsner medical center, Metairie, LA, ¹⁰University of Queensland/Ochsner Clinical School, New Orleans, LA, ¹¹Institution of Translational Research, Ochsner Health System, New Orleans, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation and the production of autoantibodies, leading to systemic multiorgan damage. SLE has…
Abstract Number: 2055 • ACR Convergence 2022
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Alfredo Aguirre¹, Mimi Kim², Kosalaram Goteti³, Ying Li³, Amy Kao⁴, Nathalie Franchimont⁵, George Kong⁵, Catherine Barbey⁶, Qing Zuraw⁷, Robert Gordon⁷, David Manner⁸, Maria Silk⁹, Teodora Staeva¹⁰, Hoang Nguyen¹¹, Richard Furie¹², Matthew Linnik¹³ and Maria Dall'Era¹⁴, ¹University of California, San Francisco, San Francisco, CA, ²Albert Einstein College of Medicine, Larchmont, NY, ³EMD Serono, Boston, MA, ⁴EMD Serono, Billerica, MA, ⁵Biogen, Cambridge, MA, ⁶Biogen, Baar, Switzerland, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Carmel, IN, ¹⁰Lupus Research Alliance, New York, NY, ¹¹Lupus Research Alliance, Houston, TX, ¹²Northwell Health, Great Neck, NY, ¹³Eli Lilly and Company, San Diego, CA, ¹⁴University of California, Division of Rheumatology, San Francisco, CA
Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 2091 • ACR Convergence 2022
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa Parra¹, Jose Meade Aguilar¹, Cynthia Crowson², Cassondra Hulshizer¹, Tina Gunderson¹, Alanna Chamberlain¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence…
Abstract Number: 2184 • ACR Convergence 2022
CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity
Marc Scherlinger¹, Hao Li², Wenliang Pan², Maria Tsokos¹ and George Tsokos², ¹BIDMC Harvard University, Boston, MA, ²Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].